Three doses of the Pfizer/BioNTech Covid-19 vaccine were effective in preventing symptomatic cases in children aged 6 months to 4 years in studies, according to US health regulators. A team from the Food and Drug Administration (FDA), a US agency similar to Anvisa, also said, in a review of study data published on Sunday (12), that there were no new safety concerns about the use of the immunizer in young children. compared to older age groups.
The assessment is the latest sign that authorities are moving closer to releasing vaccines for children under 5, the last group not eligible for immunization against Covid-19.
On Friday, the FDA released a review pointing out that two doses of Moderna’s Covid-19 vaccine are generally safe and effective in children ages 6 months to 5 years.
The FDA could make a decision next week on whether to authorize the two vaccines for use among young children, after vaccine experts advising the agency consider the data on the vaccines and make a recommendation.
Source: CNN Brasil
